Idorsia’s dual orexin receptor antagonist, the first and only drug of its kind approved in Europe for the treatment of insomnia disorder, has been awarded the inaugural Prix Galien Bridges Award in the category of “Best Biotechnology & Pharmaceutical Product”Inaugural winners are honored for breakthrough innovations in life sciences Allschwil, Switzerland – December 9, 2025Idorsia Ltd (SIX: IDIA) announces that its novel treatment for insomnia disorder has been awarded the inaugural Prix Galien Bridges Awar ...